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OBJECTIVE. To investigate the association between family history of atrial fibrillation (AF) with 
cardiovascular events (CVEs), major adverse cardiac events (MACE) and cardiovascular mortality. 
PATIENT AND METHODS. Multicenter prospective observational cohort study including 1,722 
non-valvular AF patients from February 2008 to August 2019 in Italy. Family history of AF was 
defined as the presence of AF in a first-degree relative: mother, father, sibling, or children. Primary 
outcome was a composite of CVEs including fatal/non-fatal ischemic stroke and myocardial 
infarction, and cardiovascular death. Second, we analyzed the association with MACE.  
RESULTS. Mean age was 74.6±9.4 years; 44% of women. Family history of AF was detected in 368 
(21.4%) patients, and 3.5% had ≥2 relatives affected by AF. Age of onset of AF progressively 
decreased from patients without family history AF, compared to those with single and multiple 
first-degree affected relatives (p<0.001). During a mean follow-up of 23.7 months (4,606 
patients/years) 145 CVEs (3.15%/year), 98 MACE (2.13%/year) and 57 cardiovascular deaths 
(0.97%/year) occurred. After adjustment for cardiovascular risk factors, family history of AF was 
associated with a higher risk of CVEs (hazard ratio [HR] 1.524, 95% confidence interval [CI] 1.021-
2.274, p=0.039) MACE (HR 1.917, 95%CI 1.207-3.045, p=0.006) and cardiovascular mortality (HR 2.008, 
95%CI 1.047-3.851, p=0.036). Subgroup analysis showed that this association was modified by age, 
sex and prior ischemic heart disease.  
CONCLUSION. In a cohort of elderly patients with a high atherosclerotic burden, family history of 
AF is evident in >20% of patients and was associated with an increased risk for CVEs and 
mortality. 
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Patients with atrial fibrillation  (AF) are at increased risk of cardiovascular and cerebrovascular 
ischemic complications 1-3 and mortality4.  Several risk factors may predispose to new-onset AF5, 6. 
Data from the Atherosclerosis Risk in Communities (ARIC) study showed that 56.5% of new-onset 
AF may be attributed to coexistent risk factors7, 8. They include modifiable risk factors, such as 
uncontrolled arterial hypertension, thyroid dysfunction, obesity, excessive alcohol consumption, 
sleep apnea syndrome and anticoagulation treatment9, and non-modifiable risk factors including 
increasing age, congenital heart disease, severe valvulopathy, cardiac surgery and genetic 
predisposition7, 8. Concerning the latter aspect, genome wide association studies have identified 
several genetic susceptibility loci associated with AF10, including mutations in ion channels 
expressed in atria or ventricles possessing electrophysiological properties. Nevertheless, the 
translational value of these findings remains unclear, and genetic screening is not performed for all 
patients in everyday clinical practice11. 
 
Beyond complex genetic studies, family history of AF, as defined by the presence of AF in a first-
degree relative, has been shown to confer an increased risk of early onset AF12-16. In a Danish 
population study, for example, the adjusted relative risk for incident AF was 3.37 [95% confidence 
interval (CI) 3.21–3.53] for the offspring from maternal probands, and 2.81 (95% CI 2.69–2.93) for 
offspring from paternal probands17. Furthermore, patients with persistent AF and a family history of 
AF had a higher recurrence after catheter ablation18. However, the association between family 
history of AF and clinical outcomes is more controversial, with studies reporting negative15, 19 or 
positive20 associations. 
 
In this multicenter prospective observational cohort study, our aim was to investigate the prevalence 
of family history of AF, and second, to compare the incidence rate of cardiovascular events (CVEs), 
major adverse cardiac events (MACE) and cardiovascular mortality according to the presence of 




Materials and methods 
 
Data and methods used in the analysis will be available for researchers upon reasonable request. 
We established a multicentre, prospective, observational cohort study, which included 1,722 AF 
Caucasian outpatients from the ATHERO-AF cohort at “Sapienza” University of Rome and from 
“Magna Graecia” University of Catanzaro. The ATHERO-AF study started in February 2008 and is 
still ongoing (clinicaltrials.gov NCT01882114); for this analysis, follow-up was stopped at August 
2019. 
The study included patients with both VKAs and NOACs. All patients were treated with oral 
anticoagulants, either VKAs (n=948) or non-VKA oral anticoagulants (NOACs, n=774). During the 
first clinical examination a completed personal medical history was collected, including drug 
therapy and comorbidities. The presence of AF was defined by resting 12-lead electrocardiogram; 
for patients with paroxysmal AF in sinus rhythm, a clinical documentation showing the presence of 
AF was collected. Patients were also asked about the age when AF was first diagnosed.  
Exclusion criteria were prosthetic heart valves, or the presence of any severe valvulopathies, severe 
cognitive impairment, chronic infections (Human Immunodeficiency Virus infection, Hepatitis C 
virus, Hepatitis B virus) or systemic autoimmune diseases. Subjects were also excluded from the 
study if they had active cancer or liver insufficiency (eg, cirrhosis). 
 
Definition of cardiovascular comorbidities 
Definitions of cardiovascular risk factors have been previously reported21: Arterial hypertension: 
repeatedly elevated blood pressure (≥140/≥90 mmHg) or taking antihypertensive-drugs22. Diabetes: 
a casual plasma glucose ≥200 mg/dl (11.1 mmol/l), or fasting plasma glucose ≥126 mg/dl (7.0 
mmol/l), or 2-h plasma glucose ≥200 mg/dl (11.1 mmol/l) during an oral glucose tolerance test or 
taking anti-diabetic drugs23. Heart failure: presence of signs and symptoms typical of heart failure 
or reduced ejection fraction (≤40%)24.  
 
All patients signed an informed written consent at study entry. The study was approved by the local 
ethic committee of “Sapienza” University and was conducted according to the declaration of 
Helsinki. 
 
Follow-up and definition of primary outcome 
Follow-up was performed by periodic clinical evaluations or by telephone if patients missed 1 or 




according their value of INR, and in any case, the longest period between two controls did not 
exceed 20 days. For patients on NOACs, patients after first prescription were visited at the 
outpatient clinic after 1, 3, 6 and 12 months according to ESC indications, and every 6-12 months 
afterwards. 
 
Definition of clinical endpoints 
Only the first event occurred during the follow-up was used for the analysis. Data of patients who 
were lost during follow-up were censored. 
CVEs were defined as fatal/non-fatal ischemic stroke and MI, cardiac revascularization/coronary 
bypass surgery, cardiovascular death and transient ischemic attack (TIA). The diagnosis of MI was 
formulated according to the universal definition proposed by the Joint ESC/ACCF/AHA/WHF25. If 
a patient died within 4 weeks of a stroke or heart attack, this event was recorded as fatal. Death was 
classified as cardiovascular unless a non-cardiovascular cause of death was identified. 
Cardiovascular death included sudden death, progressive heart failure, death related to surgical or 
percutaneous revascularization procedures. The diagnosis of ischemic stroke was determined by 
clinical manifestations then confirmed by radiological findings. The TIA was defined according to 
the Classification of cerebrovascular disease III26. Only the first event was used for the analysis, and 
confirmation of the primary event was made by a blinded commission that did not participate in 
patient recruitment and was not aware of the characteristics of any of the enrolled patients. We also 
analyzed the occurrence of MACE, which consisted of fatal-nonfatal MI, cardiac revascularization 
and cardiovascular death (excluding fatal and non-fatal stroke and TIA). 
 
Validation of endpoints 
Data on CVEs, MACE and CV death were prospectively collected during follow-up. When an 
event occurred, a standardized form was filled in by the investigators. Details on each event were 
registered, as well as death certificates, hospital discharge letter or copy of the medical records of 
hospitalization, and other clinical documentation (i.e. radiology and laboratory data) were also 
obtained from patients, or in case of death, from relatives of patients or from general practitioner. 
Adjudication of cardiovascular events was performed by a committee composed by physicians who 
did not participate to the recruitment of patients and was unaware of the clinical and laboratory 
characteristics of any enrolled patient. Each member of the committee independently evaluated and 
adjudicated events in a blinded manner. In case of discordant evaluation or difficult adjudication of 





Definition of family history of AF 
Family history of AF was defined as the presence of AF in at least one first-degree relative among 
mother, father, siblings or children. Multiple family history of AF was defined as the presence of AF 
in 2 or more relatives. These data were recorded during the first visit by a trained physician by 
direct face-to-face interview with patient and relatives when available. Patients were asked if they 
knew about cases of AF in the first-degree relatives, and relatives were also interviewed. In 
addition, as confirmation, they were also asked if someone of the relatives was taking anticoagulant 
drugs. Patients who were not sure about these questions were excluded. Relatives of patients have 
not been included in the study cohort.  
 
Statistical analysis 
Categorical variables were reported as a number or percentage and compared by the Pearson's χ2 
test. Continuous variables were expressed as mean ± standard deviation and Student t-test was used 
to compare means. We divided the cohort into 2 groups based on the presence/absence of family 
history of AF and we performed a descriptive analysis of groups characteristics. Annual incidence 
rates of each endpoint were calculated. Multivariable proportional hazard Cox regression analysis 
was used to estimate the relative hazard ratio (HR) with 95% confidence interval (95%CI) for each 
variable. The following variables were entered as covariates in the multivariable model: age >75 
years, age of AF onset (years), persistent/permanent AF (vs. paroxysmal), women, arterial 
hypertension, diabetes mellitus, previous cerebrovascular events, heart failure, and previous 
ischaemic heart disease. 
We built three separate survival models for: (i) CVEs; (ii) MACE (excluding thromboembolic 
events); and (iii) cardiovascular deaths. Adjusted survival curves were displayed according to the 
presence of family history of AF. Subgroup analysis by sex, age > 70 or ≤ 70 years, and prior 
cardiovascular disease was also performed. 
Only p-values below 0.05 were considered statistically significant. All the tests used are two-sided 
and the analyses were performed using electronic software packages (SPSS-25.0, SPSS Inc., IBM 






Patient characteristics according to study groups are summarised in Table 1. We included 1,722 
anticoagulated AF patients (mean age 74.6 ± 9.4 years; 44% female).  In the cohort there was a high 
prevalence of atherosclerotic risk factors, with a high prevalence of arterial hypertension (87.2%), 
diabetes mellitus (21.7%), and previous cardiovascular and cerebrovascular ischemic events (17.3% 
and 14.5%) (Table 1).  
 
A family history of AF was detected in 368 (21.4%) patients. Of these, 3.5% had more than one 
first-degree family member with AF (Figure 1, Panel A). The relatives that were most frequently 
affected by AF were siblings (51.9%), followed by parents (32.3% and 21.2%, mother and father 
respectively) and children (6.8%), as shown in Figure 1, Panel B. 
 
Patients with family history of AF were younger than those without but no other significant 
difference regarding cardiovascular risk factors was found (Table 1).  Of note, the age of onset of 
AF progressively decreased from patients without familial history, to those with single and multiple 
first-degree relatives affected, as shown in Figure 2 (p<0.001).  
 
Survival analysis 
Cardiovascular events.  
During a mean follow-up of 23.7 months (yielding 4,606 patients/years) 145 CVEs occurred 
(3.15%/year) and 39 patients were lost and other 14 were censored because newly diagnosed with 
cancer. On multivariable Cox regression analysis (Table 2), family history of AF was an independent 
predictor for CVEs, after adjustment for traditional cardiovascular risk factors. Further independent 
risk factors for CVEs were age ≥75 years, heart failure, previous ischaemic heart disease, previous 
IS/TIA and age of AF onset (Table 2). Figure 3, Panel A shows the adjusted survival probability 
free from CVEs of patients with and without family history of AF. 
 
Major adverse cardiovascular events (MACE).  
The MACE endpoint (excluding thromboembolic events) occurred in 98 patients (2.13%/year). On 
multivariable Cox proportional regression analysis, we found that the family history of AF was 
independently associated with MACE occurrence (Table 3). Other risk factors for MACE were the 
presence at baseline of heart failure, a history of ischemic heart disease and the age of onset of AF 
(Table 3). Figure 3, Panel B shows the adjusted survival probability free from MACE of patients 





Cardiovascular death.  
In our cohort, 57 cardiovascular deaths occurred (0.97%/year). On multivariable Cox survival 
analysis (Table 2) family history of AF was an independent predictive risk factor for cardiovascular 
death, together with age of onset of AF, heart failure and previous ischaemic heart disease. Figure 
3, Panel C shows the adjusted survival probability free from cardiovascular death of patients with 
and without family history of AF. 
Subgroup analysis 
Similar results were obtained using age as continuous variable for all the three endpoints considered 
(Supplementary table 1). 
A subgroup analysis according to age, showed that the association between family history of AF 
and risk of CVEs, MACE and CV death was evident in patients aged >70 years but not in those ≤70 
years (Table 3). When we divided patients according to prevalent cardiovascular disease, we found 
that the association between family history of AF and risk of CVEs, MACE and CV death was 
evident only in patients with prior coronary artery disease. Finally, when analysis by sex, showed a 
significant association between family history of AF with MACE and CV death in men but not in 








In this multicenter prospective observational cohort study, our principal finding was that more than 
20% of patients with AF have a first-degree relative suffering from the same arrhythmia. Second, 
the presence of family history of AF was associated with an increased risk of CVEs, MACE and 
cardiovascular mortality. 
The data from our work agree with the previous studies that also reported that the presence of family 
history of AF was a risk factor for early new-onset AF compared with patients without a family 
history of AF12, 27, 28. We also found that when ≥2 first-degree relatives had AF, the age of onset of 
AF was even lower than patients with only one affected family member (62 vs. 67 years, 
respectively).  
In the present study, which included Caucasian elderly AF patients with multiple atherosclerotic 
risk factors, family history of AF was associated with an increased risk of ischemic complications, 
such as CVEs, MACE and cardiovascular mortality.  
Our findings are partially in contrast with previous studies on this subject. For example, a Danish 
retrospective study showed no difference in mortality and thromboembolic risk in patients with and 
without family history of AF19. However, some important differences between our study and the 
Danish cohort may potentially account for this difference. For instance, the mean age of the Danish 
patients was 50 years, compared to 75 years in the present study; moreover, only 20% of that study 
were female, and there was a very low prevalence of cardiovascular risk factors compared to our 
cohort (eg. hypertension 27.1% vs 87.2% and diabetes 3.8% vs. 21.7%, respectively)19. A more 
recent large study from Taiwan included 244,067 patients with AF, and also showed no association 
between family history of AF and risk of MACE15. Even in this study, the majority of patients were 
relatively young (82.1% were aged <65 years), only 13.6% of female, and 34.5% were 
hypertensive15.  
What should also be taken into consideration is that all patients in our study were anticoagulated, 
whilst in both of the two studies mentioned above, there was a very low proportion of patients was 
on treatment with oral anticoagulants: for example, <30% in the Danish cohort19 and <3% in the 
Taiwan study15.  This may have affected the rate of cardiovascular events registered in the studies. 
Finally, one large Canadian study showed that the incidence rates for stroke/TIA were higher in 
offspring with a parental history of AF than those without (195.0 vs. 156.6 per 100 000 person-
years)20. Also, parental AF was also associated with elevated risk in offspring of stroke/TIA (HR 




Our study has clinical implications. The significantly lower age of onset of AF in patients with 
single and multiple family history of AF implies that subjects with a first-degree suffering from AF 
should be advised to perform screening and clinical evaluation to detect new-onset AF. This may 
lead to a potential saving of health-related costs related to AF complications29. The age of onset of 
AF in our study, likely representing the length of the disease since AF was first diagnosed, was 
independently associated with the ischemic risk, again reinforcing the need for early screening of 
relatives of patients affected by AF.  
Furthermore, the significant association between family history of AF and outcomes may represent a 
new risk factor which may easily be obtained by an accurate interview of the patient during the first 
visit. This information may turn particularly useful in some subgroups of patients, such as those in 
whom the choice whether to start or not an oral anticoagulation treatment is uncertain. Thus, the 
presence of a family history of AF, especially if multiple, may help physician in the decision-
making process. 
Subgroup analysis showed that the association between family history of AF and cardiovascular 
outcomes is strongly modified by sex, age and prevalent cardiovascular disease, underlying that 
there is complex interaction between polygenic factors, demographic characteristics and 
environmental variables. In particular, we did not find a significant difference in the proportion of 
women between the two groups of patients with and without family history of AF, which is in 
contrast with a previous study on 5,884 AF patients from the Health eHeart Study30. Female sex 
was not associated with cardiovascular outcomes in our study, differently from findings from the 
RACE II trial in which female sex was associated with the composite of CVEs but not with 
increased cardiovascular death31. Of interest, the association between family history and outcomes 
was stronger in women than men, suggesting a sex-based difference. Further study on the 
relationship between family history of AF and sex are needed. 
The mechanisms underlying our results may be several. The similar baseline cardio-metabolic 
characteristics of patients with and without family history of AF suggest that other variables than 
the traditional cardiovascular risk factors may confer an increased risk of both early onset of AF 
and of cardiovascular events in these patients. These aspects may pertain structural and 
electrophysiology characteristics, as suggested by documented genetic-based alterations in some 
proteins like myosin32 or ion channels33. It would be therefore interesting to study heart structure 
and function as well as electrical conduction in patients with family history of AF. Genome 
sequencing of patients with family history may also provide novel insights on this topic and may 





The burden of family history seems also to influence the risk of AF, as shown by individuals with 
≥1 affected parent and ≥1 affected sibling in whom the odds ratio for having new AF was 5.56 
(95% CI 4.99 to 6.20). This is in keeping with our study in which patients with multiple relatives 
affected by AF have a lower age of onset of AF compared to those with only 1 or none affected 
relative35. 
Limitations 
Our study has limitations. First, this is an observational study, and it is not possible to establish a 
cause-effect relationship between the presence of family history of AF and the onset of ischemic 
complications. Second, the presence of family history of AF was recorded through a direct face-to-
face interview with the patient and with relatives (when available), and although performed by 
dedicated staff, may still present inaccuracies in recording of familial disorders. However, when 
patients or relatives were not sure about the type of cardiac disorder, these were excluded. 
Furthermore, we cannot exclude that other factors/diseases may contribute to the onset of AF in 
relatives of patients. Third, our data comes from a cohort of all Caucasian elderly patients, thus the 
prevalence and impact on outcomes cannot be applied to populations of other ethnic groups. Fourth, 
the cohort was composed by patients enrolled in a hospital-based anticoagulation clinic. Finally, we 
did not investigate differences in the association between single or multiple family history of AF 
links and ischemic complications, due to the limited number of patients with multiple family history. 
Similarly, larger studies are needed to analyse the relationship between different type of family 
history of AF (i.e. mother or father) and CVEs. 
Conclusion 
In a cohort of elderly patients with a high atherosclerotic burden, family history of AF is evident in 
>20% of patients and was associated with an increased risk for CVEs and mortality. First-degree 
relatives of patients with AF should undergo screening and clinical evaluation to detect new-onset 
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Figure 1. Panel A. Prevalence of single and multiple familiarity for atrial fibrillation (AF) in first 
degree relatives in the whole cohort. Panel B. Prevalence of different types of familiarity. 
Figure 2.  Age of onset of atrial fibrillation in patients without and in those with single and multiple 
family history of AF.  
Figure 3. Adjusted Cox survival curves in patients with and without family history of AF for 
cardiovascular events (Panel A), major adverse cardiovascular events (MACE, Panel B) and 





















 (n= 368) 
p-value* 
Age (years) 74.6±9.4 75.2±9.22 72.3±9.73 <0.001# 
Age >75 years (%) 52.2 54.2 44.8 0.001§ 
Age of AF onset (years) 69.9±11.6 70.8±11.6 66.3±10.88 <0.001# 
Persistent/permanent AF (%) 56.4 57.3 53.4 0.192§ 
Women (%) 49.9 49.2 52.9 0.217§ 
NOAC (vs VKAs) 44.9 44.5 46.7 0.443§ 
Arterial hypertension (%) 87.2 87.4 86.6 0.724§ 
Diabetes mellitus (%) 21.7 22.1 19.9 0.391§ 
Previous cerebrovascular events 
(%) 
14.5 14.8 13.4 0.558§ 
Heart failure (%) 16.3 16.8 14.4 0.297§ 
Previous ischaemic heart disease 
(%) 
17.3 17.2 17.6 0.876§ 
CHA2DS2VASC score 3.5±1.5 3.54±1.48 3.35±1.54 0.026
# 
AF: atrial fibrillation, NOAC: non-vitamin K anticoagulants, VKA: vitamin K antagonist 









Table 2. Multiple Cox regression analysis of risk factors for cardiovascular events (Panel A), 
major adverse cardiovascular events (Panel B), and cardiovascular death (Panel C). 
 
Panel A. CVEs 
Hazard 
Ratio 
95% Confidence Interval 
Lower                Upper 
p-value 
Age ≥ 75 years 1.60 1.02 2.50 0.042 
Persistent/permanent AF 0.88 0.62 1.23 0.442 
Age of AF onset 1.04 1.02 1.07 0.002 
Female 0.78 0.55 1.10 0.159 
Arterial hypertension 1.12 0.58 2.15 0.733 
Diabetes mellitus 1.24 0.85 1.79 0.265 
Heart failure 1.90 1.30 2.78 0.001 
Previous cerebrovascular events 1.98 1.35 2.88 <0.001 
Previous ischaemic heart disease 1.73 1.20 2.49 0.003 
Family history of AF 1.52 1.02 2.27 0.039 




95% Confidence Interval 
Lower                Upper 
p-value 
Age ≥ 75 years 1.32 0.76 2.28 0.321 
Persistent/permanent AF 1.00 0.66 1.52 0.996 
Age of AF onset 1.05 1.02 1.08 0.002 
Female 0.80 0.52 1.21 0.287 
Arterial hypertension 1.30 0.57 3.00 0.535 
Diabetes mellitus 1.16 0.74 1.83 0.521 
Heart failure 2.18 1.40 3.41 0.001 
Previous cerebrovascular events 1.47 0.90 2.40 0.126 
Previous ischaemic heart disease 1.98 1.28 3.06 0.002 
Family history of AF 1.92 1.21 3.05 0.006 
Panel C. Cardiovascular death 
Hazard 
Ratio 
95% Confidence Interval 
Lower                Upper 
p-value 
Age ≥ 75 years 1.65 0.73 3.72 0.227 
Persistent/permanent AF 1.32 0.74 2.37 0.348 
Age of AF onset 1.10 1.05 1.15 <0.001 
Female 0.72 0.42 1.26 0.253 
Arterial hypertension 4.21 0.58 30.58 0.155 
Diabetes mellitus 1.39 0.77 2.50 0.275 
Heart failure 2.18 1.22 3.90 0.008 
Previous cerebrovascular events 1.65 0.90 3.04 0.106 
Previous ischaemic heart disease 1.81 1.02 3.21 0.044 
Family history of AF 2.01 1.05 3.85 0.036 








Table 3. Adjusted hazard ratio (95% confidence interval) for family history of AF according 
to specific subgroups of patients. 
 
 CVEs MACE CV death 
Age > 70 years 1.58 (1.00-2.50) 1.83 (1.07-3.14) 2.15 (1.06-4.37) 
Age ≤ 70 years 1.24 (0.55-2.81) 2.20 (0.85-5.70) 1.16 (0.21-6.46) 
Men 1.39 (0.80-2.41) 1.46 (0.80-2.80) 1.72 (0.71-4.18) 
Women 1.74 (0.95-3.17) 3.04 (1.52-6.11) 2.69 (1.01-7.22) 
Prior cardiovascular disease 2.11 (1.15-3.88) 2.85 (1.44-5.65) 3.06 (1.21-7.77) 
No prior cardiovascular 
disease 
1.22 (0.70-2.10) 1.36 (0.70-2.62) 1.26 (0.47-3.37) 
CV: cardiovascular, CVEs: cardiovascular events, MACE: major adverse cardiac events  
 
Covariates were the same used in table 2 (excluding the variable used to categorize results). 
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